Antitumor Activity of Natural Products and Related Compounds, 2nd Volume

Topic Information

Dear Colleagues,

Cancer is one of the leading causes of morbidity and mortality in humans today, and the number of people affected by cancer is growing. As a result, the search for new antitumor agents that may be more effective and secure than existing treatments is an ongoing effort.

Nature provides a wide range of compounds with a great variety of chemical scaffolds and distinct bioactivity profiles. Indeed, natural products are a rich source of bioactive molecules that, over the years, have found application in the treatment of many diseases, including cancer. Natural products have played an important role in chemotherapy and chemoprevention by providing antitumor drugs, such as camptothecin, doxorubicin, paclitaxel, vinblastine, and vincristine, as well as in understanding the cellular and molecular mechanisms underlying antitumor activity. Significant advances in natural source isolation and extraction techniques have enabled the identification of novel lead compounds as useful starting points for the generation of optimized molecules with enhanced therapeutic potential via semi-synthetic or synthetic processes.

The focus of this Topic is on natural substances derived from plants or animals, as well as their synthetic derivatives, which have been investigated for their ability to counteract cancer progression.

Dr. Barbara De Filippis
Dr. Alessandra Ammazzalorso
Dr. Marialuigia Fantacuzzi
Topic Editors

Keywords

Participating Journals

Journal Name	Impact Factor	CiteScore	Launched Year	First Decision (median)	APC
Biomolecules biomolecules	5.5	8.3	2011	16.9 Days	CHF 2700	Submit
Cancers cancers	5.2	7.4	2009	17.9 Days	CHF 2900	Submit
International Journal of Molecular Sciences ijms	5.6	7.8	2000	16.3 Days	CHF 2900	Submit
Molecules molecules	4.6	6.7	1996	14.6 Days	CHF 2700	Submit
Scientia Pharmaceutica scipharm	2.5	6.4	1930	22.7 Days	CHF 1000	Submit
Pharmaceutics pharmaceutics	5.4	6.9	2009	14.2 Days	CHF 2900	Submit

MDPI Topics is cooperating with Preprints.org and has built a direct connection between MDPI journals and Preprints.org. Authors are encouraged to enjoy the benefits by posting a preprint at Preprints.org prior to publication:

1. Immediately share your ideas ahead of publication and establish your research priority;
2. Protect your idea from being stolen with this time-stamped preprint article;
3. Enhance the exposure and impact of your research;
4. Receive feedback from your peers in advance;
5. Have it indexed in Web of Science (Preprint Citation Index), Google Scholar, Crossref, SHARE, PrePubMed, Scilit and Europe PMC.

Published Papers (2 papers)

Order results

Content type Publication Date

Result details

Normal Extended Compact

Journals

All Biomolecules Cancers IJMS Molecules Sci. Pharm. Pharmaceutics

Show export options expand_more Show export options expand_less

Select all

Export citation of selected articles as:

Plain Text BibTeX BibTeX (without abstracts) Endnote Endnote (without abstracts) Tab-delimited RIS

Error

Oops... you haven't selected anything for export.

Ok

clear

attachment

Supplementary material:
Supplementary File 1 (ZIP, 776 KiB)

15 pages, 5364 KiB  

Open AccessArticle

Synergistic Anti-Cancer Effects of ERB-041 and Genistein through Estrogen Receptor Suppression-Mediated PI3K/AKT Pathway Downregulation in Canine Mammary Gland Tumor Cells

by Min-Jae Yoo, Ye-Ji Jang, Sang-Youel Park, Ja-Wun Choi and Jae-Won Seol

Int. J. Mol. Sci. 2024, 25(5), 2466; https://doi.org/10.3390/ijms25052466 - 20 Feb 2024

Cited by 1 | Viewed by 657

Abstract

Canine-mammary-gland tumors (CMTs) are prevalent in female dogs, with approximately 50% of them being malignant and often presenting as inoperable owing to their size or metastasis. Owing to poor outcomes, effective alternatives to conventional chemotherapy for humans are necessary. Two estrogen receptors, estrogen [...] Read more.

Canine-mammary-gland tumors (CMTs) are prevalent in female dogs, with approximately 50% of them being malignant and often presenting as inoperable owing to their size or metastasis. Owing to poor outcomes, effective alternatives to conventional chemotherapy for humans are necessary. Two estrogen receptors, estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ), which act in opposition to each other, are involved, and CMT growth involves ERα through the phosphoinositide 3-kinases (PI3K)/AKT pathway. In this study, we aimed to identify the synergistic anti-cancer effects of ERB-041, an ERβ agonist, and genistein, an isoflavonoid from soybeans known to have ERβ-specific pseudo-estrogenic actions, on CMT-U27 and CF41.Mg CMT cell lines. ERB-041 and genistein synergistically inhibited cell proliferation and increased the number of annexin V-positive cells in both cell lines. Furthermore, we observed a synergistic increase in the Bax/Bcl-2 ratio and cleaved caspase-3 expression. Additionally, cell-cycle arrest occurred through the synergistic regulation of cyclin D1 and cyclin-dependent kinase 4 (CDK4). We also found a synergistic decrease in the expression of ERα, and the expression of proteins involved in the PI3K/AKT pathway, including p-PI3K, phosphatase and tensin homolog (PTEN), AKT, and mechanistic target of rapamycin (mTOR). In conclusion, ERB-041 and genistein exhibited a synergistic anticancer effect on CMTs, suggesting that cotreatment with ERB-041 and genistein is a promising treatment for CMTs. Full article

(This article belongs to the Topic Antitumor Activity of Natural Products and Related Compounds, 2nd Volume)

►▼ Show Figures

Figure 1

attachment

Supplementary material:
Supplementary File 1 (ZIP, 2167 KiB)

14 pages, 4297 KiB  

Open AccessArticle

The Use of Schisandrin B to Combat Triple-Negative Breast Cancers by Inhibiting NLRP3-Induced Interleukin-1β Production

by Chun-Ming Chang, Ting-Ruei Liang and Ho Yin Pekkle Lam

Biomolecules 2024, 14(1), 74; https://doi.org/10.3390/biom14010074 - 05 Jan 2024

Viewed by 1203

Abstract

Triple-negative breast cancer (TNBC) is the most aggressive and fatal breast cancer subtype. Nowadays, chemotherapy remains the standard treatment of TNBC, and immunotherapy has emerged as an important alternative. However, the high rate of TNBC recurrence suggests that new treatment is desperately needed. [...] Read more.

Triple-negative breast cancer (TNBC) is the most aggressive and fatal breast cancer subtype. Nowadays, chemotherapy remains the standard treatment of TNBC, and immunotherapy has emerged as an important alternative. However, the high rate of TNBC recurrence suggests that new treatment is desperately needed. Schisandrin B (Sch B) has recently revealed its anti-tumor effects in cancers such as cholangiocarcinoma, hepatoma, glioma, and multi-drug-resistant breast cancer. However, there is still a need to investigate using Sch B in TNBC treatment. Interleukin (IL)-1β, an inflammatory cytokine that can be expressed and produced by the cancer cell itself, has been suggested to promote BC proliferation and progression. In the current study, we present evidence that Sch B can significantly suppress the growth, migration, and invasion of TNBC cell lines and patient-derived TNBC cells. Through inhibition of inflammasome activation, Sch B inhibits interleukin (IL)-1β production of TNBC cells, hindering its progression. This was confirmed using an NLRP3 inhibitor, OLT1177, which revealed a similar beneficial effect in combating TNBC progression. Sch B treatment also inhibits IL-1β-induced EMT expression of TNBC cells, which may contribute to the anti-tumor response. Full article

(This article belongs to the Topic Antitumor Activity of Natural Products and Related Compounds, 2nd Volume)

►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less

Select all

Export citation of selected articles as:

Plain Text BibTeX BibTeX (without abstracts) Endnote Endnote (without abstracts) Tab-delimited RIS

 

Error

Oops... you haven't selected anything for export.

Ok

clear

Displaying articles 1-2